Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3323 ARTÍCULOS , VIENDO DEL 1561 AL 1575

In vivo imaging neurotransmitter function. The rat 6-hydroxydopamine model and its relevance for human Parkinson's disease

Nikolaus S, Larisch R, Vosberg H, Beu M, Hautzel H, Wirrwar A, Mueller HW, Antke C.

Nuklearmedizin. 2011;50(4):155-66. doi: 10.3413/Nukmed-0371-10-12. Epub 2011 Mar 16.

Exclusion of linkage to chromosomes 14q, 2q37 and 8p21.1-q11.23 in a Serbian family with idiopathic basal ganglia calcification

Kostić VS, Lukić-Ječmenica M, Novaković I, Dobričić V, Brajković L, Krajinović M, Klein C, Pavlović A.

J Neurol. 2011 Sep;258(9):1637-42. doi: 10.1007/s00415-011-5985-1. Epub 2011 Mar 16.

First report of a pathogenic mutation on exon 24 of the NOTCH3 gene in a CADASIL family

Valenti R, Bianchi S, Pescini F, D'Eramo C, Inzitari D, Dotti MT, Pantoni L.

J Neurol. 2011 Sep;258(9):1632-6. doi: 10.1007/s00415-011-5983-3. Epub 2011 Mar 16.

Molecular chaperones and associated cellular clearance mechanisms against toxic protein conformers in Parkinson's disease

Hinault MP, Farina-Henriquez-Cuendet A, Goloubinoff P.

Neurodegener Dis. 2011;8(6):397-412. doi: 10.1159/000324514. Epub 2011 Mar 16.

[Premotor diagnosis of Parkinson's disease]

Morales-Briceño H, Cervantes-Arriaga A, Rodríguez-Violante M.

Gac Med Mex. 2011 Jan-Feb;147(1):22-32.

Astrocytes in Parkinson's disease and DJ-1

Hauser DN, Cookson MR.

J Neurochem. 2011 May;117(3):357-8. doi: 10.1111/j.1471-4159.2011.07217.x. Epub 2011 Mar 17.

Alterations in striatal oxidative stress level produced by pharmacological manipulation of dopamine as shown by a novel synthetic marker molecule

Aluf Y, Vaya J, Khatib S, Finberg JP.

Neuropharmacology. 2011 Jul-Aug;61(1-2):87-94. doi: 10.1016/j.neuropharm.2011.03.006. Epub 2011 Mar 21.

Advances in metal-induced oxidative stress and human disease

Jomova K, Valko M.

Toxicology. 2011 May 10;283(2-3):65-87. doi: 10.1016/j.tox.2011.03.001. Epub 2011 Mar 23.

Impact of ω-3 fatty acids in Parkinson's disease

Bousquet M, Calon F, Cicchetti F.

Ageing Res Rev. 2011 Sep;10(4):453-63. doi: 10.1016/j.arr.2011.03.001. Epub 2011 Mar 23.

Voltage-dependent mania after subthalamic nucleus deep brain stimulation in Parkinson's disease: a case report

Chopra A, Tye SJ, Lee KH, Matsumoto J, Klassen B, Adams AC, Stead M, Sampson S, Kall BA, Frye MA.

Biol Psychiatry. 2011 Jul 15;70(2):e5-7. doi: 10.1016/j.biopsych.2010.12.035. Epub 2011 Mar 16.

Impulse control disorders in Parkinson disease: a multicenter case--control study

Voon V, Sohr M, Lang AE, Potenza MN, Siderowf AD, Whetteckey J, Weintraub D, Wunderlich GR, Stacy M.

Ann Neurol. 2011 Jun;69(6):986-96. doi: 10.1002/ana.22356. Epub 2011 Mar 17.

Autophagic pathways in Parkinson disease and related disorders

Xilouri M, Stefanis L.

Expert Rev Mol Med. 2011 Mar 21;13:e8. doi: 10.1017/S1462399411001803.

[Clinical rehabilitative effect of memantine on cognitive and motor disorders in patients with Parkinson's disease]

Li W, Zhao JH, Sun SG, Zhang JW, Suo AQ, Ma MM.

Zhonghua Yi Xue Za Zhi. 2011 Feb 1;91(5):301-3.

AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial

LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Thomas K, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Van Meter L, Sapan CV, During MJ, Kaplitt MG, Feigin A.

Lancet Neurol. 2011 Apr;10(4):309-19. doi: 10.1016/S1474-4422(11)70039-4.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias